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Abstract 
Background: Monitoring adverse drug reactions (ADRs) through pharmacovigilance are vital to patient safety. 
Spontaneous ADR reporting is one method of pharmacovigilance, and in Canada all reporter types admitted to 
report an ADR to the Canadian Vigilance Program at Health Canada. Reports are submitted to Health Canada by post, 
telephone, or via the internet. The Canada Vigilance Program electronically records submitted information to detect 
medication safety alerts. Although previous studies have shown differences between patients and healthcare profes-
sionals (HCPs) on the types of drugs and reactions reported, relatively little is known about the importance of patient 
reports to pharmacovigilance activities. This article proposed a multi-method approach to evaluate the importance 
of patient ADR reporting on pharmacovigilance activities, by systematically review the available literature, comparing 
patient—versus HCPs-generated ADR reports that were submitted to the Canada Vigilance Program, and exploring 
patient views and experiences regarding the Canadian ADR reporting system.
Methods: Guided by a risk-perception theoretical lens, the proposed multi-methods research study will involve three 
phases. Phase I is a systematic review of all studies that analyse the factors influence ADR reporting by patients to the 
pharmacovigilance schemes. Phase II is a descriptive statistical analysis of all ADR reports received by the Canada Vigi-
lance Program database between 1 January 2000 and 31 December 2014 from patients and HCPs to compare ADRs 
reported by patients with those reported by HCP reports in terms of ADR seriousness, ADR classification by system 
organ class, and the medication involved based on the anatomical therapeutic class system. In phase III, an interpre-
tative descriptive approach will be used to explore patient’s views and experiences on ADR reporting and usability 
of the Canadian Vigilance ADR report. Participants will be purposefully selected to ensure diverse backgrounds and 
experiences. Interviews will be digitally-recorded, transcribed verbatim, and inductively analysed to identify themes. 
Patients will be interviewed until theoretical saturation is achieved.
Discussion: Findings from this research will highlight the role of the patients in directly reporting ADRs, and provide 
information that may guide streamline and optimizing patient ADR reporting. Policy makers, public health officials, 
and regulatory agencies will require this critical information in order to improve medication safety in Canada and 
worldwide.
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Background
Adverse drug reactions (ADRs) are a worldwide prob-
lem that affects all drugs and their users. They cause 
significant disability and mortality, and are expected to 
be associated with an economic drain on the healthcare 
system (Bates et al. 1995; Oshikoya and Awobusuyi 2009). 
ADRs are monitored in many countries and by the World 
Health Organization (WHO) since the 1960s using spon-
taneous reporting systems, also called ‘early warning’ 
systems (Stricker 2004). Pharmacovigilance is the science 
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and activities relating to monitoring, detection, assess-
ment, understanding, and prevention of ADRs (Aagaard 
et  al. 2009). Monitoring product safety has been tradi-
tionally done by passive surveillance (voluntary reports) 
or the collection of spontaneously reported adverse 
events from healthcare providers and consumers follow-
ing the administration of a medicinal product (Sharrar 
and Dieck 2013).
In the beginning of ADR monitoring, only doctors and 
dentists were allowed to submit ADR reports to these 
databases (Aagaard et al. 2009). But, because the health 
agencies started focusing more on patients’ safety, in 
1995 all drug manufacturers, world widely, were man-
dated to report ADRs (WHO 2002). Later, other health-
care professionals (HCPs), pharmacists, and patients 
were allowed to report ADRs in hope that this would 
increase the volume and quality of ADR reports (Aagaard 
et al. 2009).
Spontaneous direct patient reporting may prove to 
be essential for continuous improvement and success-
ful pharmacovigilance. However, the literature is defi-
cient regarding the role of direct patient reporting, 
and its effects, on pharmacovigilance activities (Herx-
heimer et al. 2010). Much controversy remains among 
experts concerning the utility and efficacy of incor-
porating patient ADR reports into pharmacovigilance 
guidelines and protocols (Mitchell et  al. 1988; Hazell 
et al. 2013a, b). Some researchers believe that patient 
ADR reporting is detrimental to pharmacovigilance 
activities while others fully support it and agreed 
that direct patient reporting is necessary to add that 
extra layer for good pharmacovigilance since patients 
as users of medications have first-hand knowledge of 
their experiences with ADRs (Aagaard et al. 2009; van 
Grootheest and de, Graaf L, de, 2003; Blenkinsopp 
et al. 2007).
To date, few countries, including Canada, recognize 
patient-submitted ADR reports in their pharmacovigi-
lance activities (Aagaard and Hansen 2010). One of the 
studies showed that the quality of direct patient report-
ing has been found to be similar to that of reports from 
HCPs and the spontaneous patients reporting of serious 
adverse drug reactions were helpful in detecting drug 
alert (Aagaard et al. 2009; Blenkinsopp et al. 2007). Other 
study showed that compared with other sources, patients 
reported different categories of ADRs for different types 
of medicines (Aagaard et  al. 2009). Patients, through 
their reports, can offer a more direct and precise view of 
what is actually occurring during the treatment period 
(Blenkinsopp et  al. 2007). The reports from patients 
provide insight that reports from HCPs simply cannot. 
Unlike reports from physicians, these reports describe 
how the adverse effects affect people’s lives (Herxheimer 
et  al. 2010). Patient ADRs have the potential to express 
descriptive details of the ADR.
Patients often differ in their risk perception with 
respect to drug therapy when compared to HCPs (Aron-
son 2006). In one of the studies that conducted in the 
UK, patients’ reports differ from HCPs reports in terms 
of categorising event types (Blenkinsopp et al. 2007). In 
another study participants were requested to provide 
their risk perception of ADRs associated with 13 different 
drug classes. The findings showed that the two groups 
perceived ADR risks differently. Among HCPs, anti-
coagulants and non-steroidal anti-inflammatory drugs 
[NSAIDs] were ranked as the most dangerous drugs with 
respect to ADRs, whereas patients did not rank NSAIDS 
among the most dangerous drugs and believed that aspi-
rin [an NSAID] posed the least threat (Bongard et  al. 
2002). In Denmark, consumers were more likely to report 
ADRs from SOCs: ‘nervous system disorders’; ‘psychiat-
ric disorders’ and ‘reproductive system and breast disor-
ders’ (than other sources (Aagaard and Hansen 2010).
Furthermore, by allowing direct patients spontane-
ous reporting, we are allowing the patient to be actively 
involved in their treatment. With the added patient 
reports to those of HCPs, the spontaneous surveillance 
database can acquire data rich in additional information 
about ADRs (Hammond et al. 2007). It could be argued 
that this only speeds up the drug alert detection process.
The literature review has demonstrated a gap in knowl-
edge of one of the earliest safety reporting system active 
since 1965. No studies were found that compare and con-
trast patient reports against HCP reports in Canada using 
adverse reaction reporting system of Canada. Under-
standing how patients are involved in ADR reporting can 
provide new insights into the importance and limitations 
of integrating patient-generated ADR reports into phar-
macovigilance approaches which might help in improv-
ing medication use safety in Canada. This study aimed 
to provide new insights into the importance of patients 
ADR reporting. Policy makers, public health officials, and 
regulatory agencies require this critical information to 
improve medication safety.
Objective and research questions
The objective of this protocol is to evaluate the impor-
tance of patient ADR reporting on pharmacovigilance 
activities, by systematically review the available litera-
ture, comparing patient—versus HCPs-generated ADR 
reports-based on seriousness, system organ class—ana-
tomical therapeutic class—that were submitted to the 
Canada Vigilance Program, and exploring patient views 
and experiences regarding the Canadian ADR reporting 
system. The study will involve three phases that will focus 
on the following research questions:
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1. What are the factors influencing reporting of adverse 
drug reaction by patients?
2. What types of ADRs, suspect drug classes, reac-
tion severity, and ADR-involved organ systems are 
reported by patients versus HCPs?
3. What are the views and experiences of patients 
regarding ADR reporting and the user-friendliness of 
ADR reporting in Canada?
Conceptual framework
The Risk Perception Theory will provide a theoretical 
lens to examine the differences between patients and 
HCPs perceptions in term of the number of serious 
ADRs reported by each group. It works on the concept 
that different classes of people [professionals versus non-
professionals, scientists versus the public, or, in this case, 
HCPs versus patients] have different views on the possi-
ble risks associated with some action or environment (Af 
WÅhlberg AE. 2001).
Methods
This study protocol consists of three complementary 
phases, each phase sequentially informs the next.
Phase I: Systematic review of all studies that analyse the 
factors influencing reporting ADRs by patients to the 
pharmacovigilance systems
Research question 1 What are the factors influencing 
reporting of adverse drug reaction by patients?
Methods
A systematic literature review will be guided by the 
Cochrane Handbook (Higgins and Green 2011), and 
will be structured to meet the Preferred Report-
ing Items for Systematic Reviews and Meta-Analyses 
(PRISMA) (Moher et  al. 2009) criteria. Eligible stud-
ies addressed the factors influencing ADR reporting by 
patients. The search strategy protocol will be developed 
collaboratively with an academic reference librarian to 
refine queries and characterize them in terms of ele-
ments. Study inclusion/exclusion criteria will be framed 
in a systematic manner, using the elements of a question 
and include population, intervention, comparator, and 
outcome (PICO) (Stillwell et  al. 2010) (Table  1) even 
if all these elements are not used in the formal search 
strategy.
Search strategy
The search will focus on all major databases relevant to 
the subject matter, i.e., PubMed, MEDLINE, EMBASE, 
CINAHL, PSYCINFO, ProQuest Dissertation and The-
ses, and Cochrane library. These databases will be 
searched using both medical subject heading (MeSH) 
and text search terms including: patients, consumers, 
public, adverse drug reactions, report, reporting, spon-
taneous, pharmacovigilance, and surveillance. The search 
dates will include all years for the database, i.e., from 
the earliest data sources on each database, e.g., 1947 or 
earlier, and up to December 2014. The reference lists of 
each included study will be checked to identify additional 
studies for potential inclusion. Grey literature searches 
will be performed using similar search terms.
Data extraction
All data from the included studies will be extracted using 
a data extraction form. The form will be pilot tested prior 
to commencing data extraction. After the identification 
of studies, duplicates will be removed and two independ-
ent reviewers will conduct three levels of screening. Level 
one of screening is to determine study relevance to the 
overall objective of the systematic review and this will 
include title screening. Level two screening will be a 
title and abstract screen based on the inclusion/exclu-
sion criteria. Level three screening will include review-
ing the final group of studies identified by both reviewers 
as meeting the inclusion criteria. A second reviewer will 
verify the accuracy of extracted data. Study data qual-
ity and study bias risk assessments will be performed. 
The two independent reviewers will assess the quality of 
included studies using the appropriate critical appraisal 
skills programme (CASP) checklist (Milne and Oliver 
1996).
Table 1 Systematic review inclusion/exclusion criteria
Include Exclude
Study Design Regardless of methodology, eligible studies answered the  
question: what factors influence reporting ADRs by patients?
–
Population Studies addressing patients view and perceptions on ADRs  
reporting
Studies addressing: the view and perception of HCPs on ADRs 
reporting, the role of HCPs in ADR reporting, ADRs reported by 
HCPs, restricted to specific drugs or therapeutic class
Setting No restriction on setting –
Language All studies in English. Non-English studies will be converted  
to English using Google Translate (due to resources limitation)
–
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Data analysis
The data will be synthesized by classifying the different 
study types, and by comparing and contrasting study 
findings. Characteristics of included studies will be ana-
lysed descriptively and the results will present in a nar-
rative format recommended by the PRISMA (Preferred 
Reporting Items for Systematic Reviews and Meta-Analy-
ses) statement (Liberati et al. 2009).
Bias
A prior plan was made to minimize the risk of bias (Har-
tling et al. 2009) using Assessment of Multiple Systematic 
Reviews (AMSTAR) (Shea et  al. 2009). The systematic 
review protocol was established, and the two researchers 
will be involved in screening the identified literature and 
will participate in data extraction.
Phase II: Observational retrospective descriptive 
statistical comparison of ADR reports from patients 
versus healthcare professionals
Research questions and hypothesis
1. Are there a significant difference in distribution of 
ADRs between reports (patients vs. HCPs) based on 
ADRs seriousness)? Does the trend change?
2. Are there significant differences in distribution of 
ADRs between reporters (patients’ vs HCPs) for sys-
tem organ classification (SOC)?
3. Are there significant differences in distribution of 
ADRs between reporters (patients’ vs HCPs) for the 
suspected drug class involved?
Methods
Study design
An observational—retrospective cross-sectional study 
design will be used. The study will include all ADR 
reports submitted to the Canadian Vigilance Database 
from January 2000 through December 2014, inclusive. 
Using 14  years data will help to observe the changes in 
patients reporting. The ADR report analysis will com-
pare content from patients—versus HCPs-submitted 
reports in terms of ADR seriousness, ADR classification 
by system organ class, and the medication involved based 
on the anatomical therapeutic class system (ATC). Only 
ADRs classified as ‘serious’ will be analysed because iden-
tifying serious ADRs are the primary focus of spontane-
ous reporting systems and are of particular public health 
interest. The unit of analysis will be the ADR.
Study setting
The Canada Vigilance database contains all spontaneous 
ADR reports in Canada that were reported directly by 
HCPs, patients, and pharmaceutical companies. An ADR 
report is defined by the following four criteria, which 
must be included in all reports: (1) patient information; 
(2) the suspected medicine(s); (3) patient outcome infor-
mation (s); and (4) reporter. Reports are categorized in 
the database by the degree of seriousness according to 
the Council for International Organizations of Medical 
Sciences criteria (Health Canada 2007). Health Canada 
Vigilance handles the ADR reports from the patients 
the same way it handles reports from other sources. The 
Canadian Vigilance database defines the following four 
categories of persons submitting reports to the database 
as: (1) community including patients, patients’ relatives, 
other members of the public; (2) hospital including HCPs 
such as physicians, pharmacists, and nurses; (3) MAHs 
including pharmaceutical companies; and (4) others 
including insurance companies.
Data extraction
Anonymized data will be extracted from the Canadian 
Vigilance ADR database based on the date reports were 
received, category of person submitting the reports, reac-
tion seriousness, medications involved, and category of 
ADRs classified by SOC. The reported ADRs were coded 
according to the Medical Dictionary for Regulatory 
Activities (MedDRA) structure on SOC. The Canadian 
Vigilance database ADR search criteria include either the 
trade names or generic name of medications reported to 
cause ADRs. Therefore, it will be necessary to manually 
translate the trade names and generic names in the phar-
macological/therapeutic subgroup of ATC level 1 to pre-
sent the ADR data in a comprehensive format (Aagaard 
et al. 2009).
Medical dictionary for regulatory activities (MedDRA)
The Medical Dictionary for Regulatory Activities (Med-
DRA) was developed by the International Conference on 
Harmonization (Journot et al. 2008). It is clinically vali-
dated international medical terminology used by regu-
latory authorities and the regulated biopharmaceutical 
and pharmaceutical industries (MedDRA 2009). Med-
DRA is needed for electronic exchange of information 
on adverse reactions between industry and regulatory 
authorities after drug registration in the European Union 
(Brown 2004). The terms in MedDRA are numerically 
coded to support electronic means of data transmittal 
and retrieval. It has 26 broad groups called system organ 
classes. MedDRA was used for coding ADR reported by 
HCPs and patients in this study. The SOC will be identi-
fied via this method and compared according to reporter.
Anatomical therapeutic chemical system (ATC)
The Anatomical Therapeutic Chemical (ATC) system 
classifies medicinal products according to their primary 
constituent, the organ or system on which they act, and 
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their chemical, pharmacological and therapeutic proper-
ties (Aagaard et al. 2009). Medicinal products are classi-
fied into groups on five different levels. The medicines are 
divided into 14 main groups (first level), with one phar-
macological/therapeutic subgroup (second level). The 
third and fourth levels are chemical/pharmacological/
therapeutic subgroups, and the fifth level is the chemi-
cal substance. The second, third, and fourth levels are 
often used to identify pharmacological subgroups if this 
is considered more appropriate than the therapeutic or 
chemical subgroups (Methodology WCCfDS 2011). In 
this study, ATC level one will be used to comprehensively 
categorize ADR data into one of 14 groups.
Data analysis
The main goal of the statistical analysis is to investigate 
the dependence between the reporter and the reported 
ADR (classified by seriousness, SOC, and ATC) using 
the “null hypothesis”. It will be assumed that there are 
no differences in the number of serious ADRs reported 
by patients versus HCPs. In case the null hypothesis is 
rejected and to ensure that any reporting differences 
between patients and HCPs will be indeed significant 
and not due to chance, the data will be analysed using 
the Chi-squared test for independence. This test is used 
to determine whether the frequency of each group is dif-
ferent from what would be expected. If the calculated 
Chi-square is high enough, then the frequencies found 
would not be expected on the basis of chance and the 
null hypothesis will be rejected. Odds ratios (ORs) will be 
calculated using a 2 ×  2 table for the reporter category 
(patients and HCPs), SOC, or ATC. Confidence intervals 
will be calculated for all ORs (95 % level). Statistical anal-
yses will be performed using SPSS version 17 statistical 
software.
PHASE III: Explore patient views and experiences 
on reporting ADRs to the Canadian vigilance database
Research question 3 What are the factors influencing 
patient ADR reporting? What are the views and experi-




An interpretive descriptive qualitative study will be con-
ducted. Interpretive description is an inductive and effec-
tive analytic approach for describing health care events 
(Thorne et al. 2009).
Participants and setting
Eligible participants will be adult patients over 18  years 
old living in Canada, have experienced an ADR, and able 
to answer questions in English or French. Purposeful 
sampling will be used to represent a range of ages (18–45, 
45–64, 65–80), sex (male, female), and patients who have 
reported a side effect to pharmacists, physicians, nurses, 
or to the Canada Vigilance Database. If we encounter 
difficulty-finding participants, we will revert to the snow-
ball technique. This approach is a sampling strategy that 
consists of seeking referrals from participants, where one 
participant gives the researcher the name of more pos-
sible participants (Creswell 1998). This technique is used 
in populations where it is difficult to identify potential 
participants. Recruitment will continue until data satura-
tion plus an additional three participants, to ensure that 
no new themes will be identified (Francis et al. 2010). We 
anticipate reaching saturation with 10 participants and 
therefore recruiting a total of 13 patients.
Participant recruitment Patients will be informed about 
study details and invited to participate through social 
media (e.g. Kijiji, Facebook, twitter), patient associations, 
and patient societies such as Patients Canada, Canadian 
Arthritis Society, or Canadian Cancer Society or Heart & 
Stroke.
Data collection
First, an email or pamphlet introducing the study will 
be given to prospective participants that express an 
interest in the study. Those willing to participate will 
have an interview set up at a convenient time and loca-
tion (including in person, telephone, or skype). During 
the interview, the researcher will explain the purpose of 
the study, describe the approximate amount of time it 
will take to complete the interview, and inform the par-
ticipant that they can withdraw from the interview at 
any time or refuse to answer any questions. Participants 
will also be informed of precisely how their data will be 
used, and an informed consent form will be provided 
for approval, signature, and return. The interview will 
be conducted using a semi-structured interview guide 
and is expected to take 30–45 min. The semi-structured 
interview guide was developed based on key sensitiz-
ing concepts from the literature on ADR reporting and 
with review by experts in pharmacy, knowledge transla-
tion to patients, and health policy. More specifically, the 
first set of questions will explore participant experiences 
with medication-related side effects, severity, who they 
report side effects to, and expectations about report-
ing. The second set of questions will focus on the user-
friendliness of the ADR reporting form that is available 
on the Canada Vigilance website. The interviewer will 
lead the patient through the form step-by-step and then 
ask questions exploring the clarity of the questions, ease 
of use, readability, and font size. Non-identifying demo-
graphic information will also be collected. Interviews 
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will be audio-taped and field notes documented by the 
researcher.
Data analysis
Interview audiotapes will be transcribed verbatim and 
analysed. Participant responses to the semi-structured 
interview questions will be analysed using interpretive 
content analysis (Huberman and Miles 1994). Interpre-
tive content analysis is an iterative process that facilitates 
analysis of text that describes processes, activities, per-
ceptions, and beliefs (Thorne et al. 2009). The qualitative 
data analysis process will use the three-step method of 
data reduction, data display, and drawing conclusions/
verification (Huberman and Miles 1994). Several tech-
niques will be used to enhance the credibility, auditabil-
ity, and transferability of the study findings (Lincoln and 
Guba 1986).
To enhance credibility, several techniques will be used 
including: (a) use of open-ended interviewing tech-
niques: tape recording and verbatim transcriptions to 
increase the accuracy of describing each participant’s 
experience;(b) share interpretation of findings with par-
ticipants to enhance accuracy from the perspective of 
the person’s living experience; and (c) extensive literature 
review (Lincoln and Guba 1986).
Auditability is the second assessment of accuracy (Lin-
coln and Guba 1986). This will be enhanced through 
presentation of enough information to the reader to see 
how the raw data lead to the interpretation.
The third criterion of assessment is transferability 
of the data by presenting enough details on the finding 
that will allow others in the discipline to determine the 
relevance of the study finding for their own practice, 
research, and theory development.
Strengths and limitations
Using secondary data from the official website of the 
Health Canada database in Phase II to compare serious 
ADRs reported by HCPs versus patients is considered 
cost-effective and time-efficient. Since the database con-
tains a large number of ADR reports; sample size is not a 
problem. But because there is no limitation on the ATCs 
in the database, this would result in a broader scope of 
information that will be obtained and more manual work 
will be needed. One of the study limitation that needs 
to be addressed is the fact that one reporter can report 
more than one ADR per report, thus resulting in ADRs 
not being truly independent. It is important to note that 
when analysing data obtained from the Canada Vigi-
lance Database, causality of a reaction by any given sus-
pect drug cannot be assumed. In addition, comparisons 
between drugs cannot be made from the available data 
(Health Canada 2011).
Using the interpretive descriptive approach in Phase III 
will create an opportunity to understand the patient per-
ception toward adverse drug reaction reporting and the 
Canadian Vigilance system which will help in interpret-
ing and understanding the results from phase II. (Thorne 
et  al. 1997). In phase III, efforts to include participants 
with various demographic characteristics, an attempt to 
broaden the recruitment, will be conducted by providing 
posters to patient associations, and use advertisements 
and Internet resources to facilitate participation.
Ethic
Secondary data obtained from the official website of 
Health Canada will be used in this research. Second-
ary data analysis does not pose a privacy risk to partici-
pants the way that primary data collection and analysis 
might, but the rights of participants will still need to be 
protected. All patient data will be anonymized and this 
study protocol had received approval of the University of 
Ottawa Research Ethics Boards in July 2014 (H05-14-18).
The ethical aspects of the research involving human 
participants will follow the guidelines of the national 
granting councils (the Canadian Institutes of Health 
Research) set out in the Tri-Council Policy Statement on 
Ethical Conduct for Research Involving Humans (Ethics 
PoR. Tri-Council Policy Statement: Ethical Conduct for 
Research Involving Humans (TCPS) 2001).
For ethics approval, four major ethical concerns were 
considered: risk, benefit, consent, and confidentiality. The 
study is not anticipated to involve direct risk to participants 
because no active intervention will occur. Participants will 
be aware that participation will be voluntary and that they 
are free to skip any question(s) that make them uncomfort-
able, and can withdraw from the study at any time.
Benefit will be explained as an opportunity to inform 
the scientific community and policy makers on current 
ADR issues and concerns. After participation, interview-
ees will be given the opportunity to ask about current 
reporting procedures to gain knowledge on the subject. 
There is no financial benefit to study participants. Each 
participant will provide written informed consent prior 
to participate in the study. The consent form will be 
explained prior to beginning the study and questions will 
be answered. Participants will be informed that steps to 
ensure confidentiality will be taken. All interviews will 
be conducted in a one-on-one manner to augment par-
ticipant confidentiality. Participants will be identified 
in all written reports by numbers only, not by names. 
Any identifying information will be removed from the 
transcripts and all electronic files will be kept password 
protected, while hardcopy files will be kept in a locked 
cabinet at researcher student office—Health Science 
Department—University of Ottawa.
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Discussion
Adverse drug reaction reporting systems need to be 
robust in order to be able to detect new drug alerts and 
improve pharmacovigilance. These systems are necessary 
to identify new reactions and to prevent potential ADRs. 
The purpose of this research is to enhance the under-
standing of safety issues associated with medication use.
The methodology proposed here has several strengths. 
First, we will systematically review all published stud-
ies that involve patients reporting to national agencies 
and compare that with what has been done in Canada. 
Second, we will descriptively analysis all ADR reports 
received by the Canada Vigilance Program database 
between January 1st 2003 and December 31st 2012 from 
patients and HCPs and compare these submitter groups 
in terms of: seriousness of suspected ADRs reported, 
distribution of ADR reports based on affected organ 
system(s), and the suspected medicine classes involved. 
And third, we will use an interpretative descriptive 
approach to explore patients’ views and experiences on 
ADR reporting and usability of the Canadian Vigilance 
ADR report. This will create an opportunity to under-
stand patient perceptions toward the Canadian Vigilance 
system and will help in interpreting and understanding 
the results from descriptive analysis of the data collected. 
One of the advantages of using the interpretive descrip-
tive methods is the ability to collect accurate data and 
provide a clear picture of the description under study 
(Ethics PoR 2001).
Findings from this research will make three significant 
contributions: (1) it will highlight the role and process of 
patients in directly reporting ADRs; (2) give new infor-
mation that may guide streamline in optimizing patient 
ADR reporting and; (3) provide policy makers, public 
health officials, and regulatory agencies with this criti-
cal information in order to improve medication safety in 
Canada.
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Appendix: Patient interview guide
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